Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Royalty Pharma plc RPRX

Healthcare Biotechnology
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including... see more

Recent & Breaking News (NDAQ:RPRX)

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing

GlobeNewswire November 6, 2014

Repros to Webcast Investor and Analyst Day on October 31st

GlobeNewswire October 27, 2014

Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile

GlobeNewswire October 21, 2014

SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Repros Therapeutics Inc. - RPRX

PR Newswire October 20, 2014

INVESTOR ALERT: Investigation of Repros Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP

Business Wire October 20, 2014

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.

PR Newswire October 20, 2014

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Repros Therapeutics Inc. (RPRX) To Contact The Firm

PR Newswire October 17, 2014

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Repros Therapeutics Inc. - RPRX

Business Wire October 17, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeutics, Inc. - RPRX

PR Newswire October 17, 2014

Upcoming FDA Meeting to be Type C Meeting

GlobeNewswire October 16, 2014

FDA Schedules Type B Pre-NDA Meeting With Repros

GlobeNewswire September 26, 2014

Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism

GlobeNewswire September 25, 2014

Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury

GlobeNewswire September 22, 2014

Repros Therapeutics Inc. (RPRX) Drops 5.67% on September 9

Equities.com September 9, 2014

Repros Therapeutics Inc. (RPRX) Jumps 18.51% on August 28

Equities.com August 28, 2014

Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism

GlobeNewswire August 27, 2014

Repros Therapeutics Inc. (RPRX) Jumps 11.76% on August 22

Equities.com August 22, 2014

Repros Therapeutics Inc. (RPRX) Jumps 5.04% on August 21

Equities.com August 21, 2014

Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results

GlobeNewswire August 11, 2014

FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo

GlobeNewswire July 16, 2014